Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $2.8 million.

  • Zevra Therapeutics' Other Working Capital Changes rose 24960.38% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 46971.64%. This contributed to the annual value of $2.2 million for FY2024, which is N/A changed from last year.
  • Per Zevra Therapeutics' latest filing, its Other Working Capital Changes stood at $2.8 million for Q3 2025, which was up 24960.38% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Other Working Capital Changes ranged from a high of $3.3 million in Q4 2024 and a low of -$1.9 million during Q3 2024
  • Moreover, its 5-year median value for Other Working Capital Changes was -$273000.0 (2021), whereas its average is $438473.7.
  • Examining YoY changes over the last 5 years, Zevra Therapeutics' Other Working Capital Changes showed a top increase of 435692.31% in 2021 and a maximum decrease of 653529.41% in 2021.
  • Over the past 5 years, Zevra Therapeutics' Other Working Capital Changes (Quarter) stood at -$541000.0 in 2021, then skyrocketed by 44.18% to -$302000.0 in 2022, then tumbled by 282.45% to -$1.2 million in 2023, then skyrocketed by 382.16% to $3.3 million in 2024, then decreased by 13.1% to $2.8 million in 2025.
  • Its Other Working Capital Changes was $2.8 million in Q3 2025, compared to $1.4 million in Q2 2025 and $560000.0 in Q1 2025.